LILRB1 and B-cell chronic lymphocytic leukemia: Our study shows that ILT2 may be involved in this immunosuppression observed in NK cells since it is overexpressed on NK cells of CLL patients, particularly in advanced patients and those showing bad prognostic features, and it is involved in the suppression of NK cell antitumor activity.